TY  - JOUR
AU  - Restelli, Umberto
AU  - García-Goñi, Manuel
AU  - Lew-Starowicz, Michal
AU  - Mierzejewski, Pawel
AU  - Silvola, Sofia
AU  - Mayoral-van Son, Jacqueline
AU  - Croce, Davide
AU  - Rocca, Paola
AU  - Crespo-Facorro, Benedicto
PY  - 2020
DO  - 10.1007/s40261-020-00944-0
UR  - http://hdl.handle.net/10668/15914
T2  - Clinical drug investigation
AB  - Schizophrenia is a low-prevalence mental disorder with a global age-standardized prevalence of 21 million people (2016). Second-generation antipsychotics (lurasidone and quetiapine XR) are recommended as the first-line treatment for schizophrenia. It...
LA  - en
KW  - Adult
KW  - Antipsychotic Agents
KW  - Chronic Disease
KW  - Cost-Benefit Analysis
KW  - Female
KW  - Hospitalization
KW  - Humans
KW  - Italy
KW  - Lurasidone Hydrochloride
KW  - Middle Aged
KW  - Models, Economic
KW  - Quetiapine Fumarate
KW  - Recurrence
KW  - Schizophrenia
KW  - Spain
KW  - State Medicine
TI  - Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR.
TY  - research article
VL  - 40
ER  -